Zhang Wei, Liu Yong-Min, Li Dong, Liu Shan, Cai Xiao-Jun, Tang Ji-Ying, Zuo Zhi-Gang, Li Xin-Hui, Zhao Yi
Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Department of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Front Immunol. 2025 May 19;16:1524842. doi: 10.3389/fimmu.2025.1524842. eCollection 2025.
Cervical cancer is a common malignant tumor in women, and human papillomavirus (HPV) infection is a major cause of cervical cancer. Tumor-infiltrating lymphocytes (TILs) are a heterogeneous group of lymphocytes primarily composed of T lymphocytes found within the tumor parenchyma and stroma. These cells can be isolated from tumor tissue, activated, expanded , and reinfused into the patient to exert an anti-tumor immune effect. As a form of personalized immunotherapy, TILs therapy has shown satisfactory efficacy and safety in advanced recurrent and metastatic cervical cancer, offering new hope to patients with advanced cervical cancer. However, TILs therapy for advanced cervical cancer still faces several limitations and challenges. This article reviews the process and latest developments in TILs therapy for advanced cervical cancer and discusses the challenges in the usage and prospects for this treatment.
宫颈癌是女性常见的恶性肿瘤，人乳头瘤病毒（HPV）感染是宫颈癌的主要病因。肿瘤浸润淋巴细胞（TILs）是一组异质性淋巴细胞，主要由存在于肿瘤实质和间质中的T淋巴细胞组成。这些细胞可从肿瘤组织中分离出来，激活、扩增后重新注入患者体内，以发挥抗肿瘤免疫作用。作为一种个性化免疫疗法，TILs疗法在晚期复发性和转移性宫颈癌中已显示出令人满意的疗效和安全性，为晚期宫颈癌患者带来了新希望。然而，晚期宫颈癌的TILs疗法仍面临一些限制和挑战。本文综述了晚期宫颈癌TILs疗法的过程和最新进展，并探讨了该疗法应用中的挑战和前景。
